AbbVie’s bispecific T‑cell engager etentamig shows positive phase 3 results in relapsed/refractory multiple myeloma

AbbVie reported that its bispecific T‑cell engager etentamig met its primary goals in the phase 3 Cervino trial for patients with relapsed or refractory multiple myeloma.

The trial demonstrated higher overall response rates and longer progression‑free survival compared with the control arm, indicating a meaningful efficacy advantage.

Safety data showed low incidence of cytokine release syndrome and few fatal infections, supporting a monthly dosing schedule that could be administered in outpatient or community settings.

According to Daejin Abidoye, M.D., the results suggest the disease is moving toward a chronic management model, allowing patients to live longer and with better quality of life.